World’s First Approved DPP-4 Inhibitor for Type 2 Diabetes Now Available In New Zealand

New Zealanders with Type 2 diabetes now have access to a new medicine which is significantly less likely to cause weight gain or dangerously low blood sugar; thanks to Merck Sharp & Dohme New Zealand's (MSDNZ) once-daily tablet, JANUVIA® (sitagliptin, MSD), which was approved for use in New Zealand today.  Click here for more.

Doctors can now upgrade osteoporosis patients to FOSAMAX PLUS

Doctors can now upgrade their osteoporosis patients to FOSAMAX PLUS® and initiate new patients straight onto the new, once-weekly combination treatment.  Click here for more.

For More Information for Health Professionals please click here.
For More Information for Patients & Caregivers please click here.